
Semaglutide Cuts BMI in Young Children With Obesity in STEP Young
Key Takeaways
- STEP Young randomized 167 children (2:1) to semaglutide vs placebo for 104 weeks; week-68 BMI change was −13.5% vs +2.7%, with 38% crossing below obesity threshold.
- Weight-based maintenance dosing followed 16-week escalation (max 2.4 mg if >60 kg; 1.7 mg if 45–60 kg), highlighting practical dose selection and tolerability-driven ceilings.
In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.
Once-weekly subcutaneous semaglutide produced significantly greater reductions in body mass index (BMI) than placebo among children aged 6 to younger than 12 years with
Trial Design and Primary Results
Investigators randomly assigned 167 children 2:1 to once-weekly semaglutide (n = 112) or placebo (n = 55) for 104 weeks, followed by a 7-week washout, at 48 sites in 9 countries. All participants received lifestyle modification counseling. Dosing was weight-based after 16 weeks of escalation: a maximum of 2.4 mg for children weighing more than 60 kg at baseline, 1.7 mg for those weighing 45 to 60 kg, or the maximum tolerated dose. The mean age was about 10 years, approximately 59% of participants were girls, and more than 85% had class 2 or 3 obesity.1
At week 68, the primary end point, mean BMI changed by −13.5% with semaglutide versus 2.7% with placebo (estimated between-group difference, −16.2 percentage points; 95% CI, −19.4 to −12.9; P < .001). At week 104, the changes were −9.4% and 8.4%, respectively (difference, −17.8 percentage points). A reduction in BMI category occurred in 79% of children receiving semaglutide vs 23% receiving placebo at week 68 (OR, 7.8; 95% CI, 3.5-17.6; P < .001), and BMI fell below the obesity threshold in 38% vs 2%.1
Although cross-trial comparisons are limited, the 56-week SCALE Kids (NCT04775082) trial of once-daily liraglutide (Saxenda; Novo Nordisk) in the same age group reported a −7.4 percentage-point BMI difference versus placebo, and the STEP TEENS (NCT04102189) trial of semaglutide 2.4 mg in adolescents reported a −16.7 percentage-point difference at 68 weeks.3,4
Cardiometabolic Measures
At week 68, waist circumference changed by −8.5 cm with semaglutide vs 2.7 cm with placebo, triglycerides by −26.3% vs 0.4%, and high-sensitivity C-reactive protein by −68.3% vs −14.4%. Systolic blood pressure and glycated hemoglobin also declined more with semaglutide. These supportive end points were not adjusted for multiplicity. In a prespecified exploratory analysis, prediabetes reverted to normoglycemia at week 68 in 93% of children receiving semaglutide versus 56% receiving placebo.1
Safety, Growth, and Counseling Considerations
Through week 111, adverse events (AEs) occurred in 96% of children receiving semaglutide and 93% receiving placebo. GI events were the most common, were mainly mild to moderate and transient, and occurred more often during dose escalation. Vomiting occurred in 70% vs 29%, diarrhea in 62% vs 35%, and nausea in 58% vs 24%. One child discontinued semaglutide because of GI events. Serious AEs occurred in 9% of each group, and no deaths occurred.1
The authors noted that vomiting at week 68 was about 2.3 times as common with semaglutide as with placebo (66% vs 29%), a higher absolute rate than reported in adults or adolescents—signaling that caregivers need anticipatory guidance during titration.1
Growth warrants attention. Median height gain was 5.7 cm with semaglutide versus 7.8 cm with placebo at week 68 and 8.8 cm versus 12.1 cm at week 104, and annual height velocity was lower with semaglutide. Bone age, bone mineral density, and Tanner stage distributions were similar between groups. The authors suggested that the smaller height gains may be explained by BMI reduction, as children with obesity can have accelerated linear growth prior to puberty. Novo Nordisk's release stated there were no safety concerns for growth or pubertal development.1,2
Psychiatric events were reported in approximately 21% of the semaglutide group and 24% of the placebo group. Study limitations included predominantly White enrollment, no screening for eating disorders, and discontinuation of the trial regimen by nearly 40% of the placebo group by week 104.1
Semaglutide is approved for adolescents aged 12 and older with obesity but remains investigational in younger children, and Novo Nordisk—which funded the trial—did not mention regulatory submission plans in its release.1,2
REFERENCES
1. Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al; STEP Young Investigators. Semaglutide for the treatment of obesity in children 6 to <12 years of age. N Engl J Med. Published online November 16, 2026. doi:10.1056/NEJMoa2604058
2. STEP Young phase 3 results: Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12. News release. Novo Nordisk. November 16, 2026. Accessed November 17, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=920731
3. Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesity — a randomized trial. N Engl J Med. 2025;392(6):555-565. doi:10.1056/NEJMoa2407379
4. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601
Related to this article








